Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL422223 | 1.00 | SIGMAR1 (0.45) | SIGMAR1HCRTR1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL422224 | 1.00 | SIGMAR1 (0.45) | SIGMAR1HCRTR1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL421591 | 0.87 | CES2 (0.46) | — | |
| SCHEMBL6910773 | 0.87 | CES2 (0.46) | — | |
| SCHEMBL421590 | 0.87 | CES2 (0.46) | — | |
| SCHEMBL1514822 | 0.85 | CES2 (0.46) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL422033 | 0.85 | CES2 (0.46) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL423786 | 0.82 | F10 (0.57) | SIGMAR1TAS1R3TAS1R1TAS1R2F10 | |
| SCHEMBL10153765 | 0.82 | F10 (0.57) | SIGMAR1TAS1R3TAS1R1TAS1R2F10 | |
| SCHEMBL423785 | 0.82 | F10 (0.57) | SIGMAR1TAS1R3TAS1R1TAS1R2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404673-B2 | Carbocyclic GlyT1 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120022042-A1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | KOLCZEWSKI SABINE (DE) | 2012-01-26 | — | — | US | disclosed |
| US-8080541-B2 | Carbocyclic GlyT-1 receptor antagonists | HOFFMAN-LA ROCHE INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20110053904-A1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053904-A1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | GRIA1, GLRA1, GRIA3 | SIGMAR1 76/4885HCRTR1 118/4885TAS1R3 942/4885 |
| US-20120022042-A1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | GRIA1, GLRA1, GRIA3 | SIGMAR1 76/4885HCRTR1 118/4885TAS1R3 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.